Regenerative medicine earns trust one study at a time. This is the published research and clinical documentation behind the PureExos ecosystem — the public record on the left, and a dedicated data room for verified practitioners.
The headline evidence — LIMFA’s university research, the exosome sourcing standards, and the regulatory picture — runs throughout the site, on the LIMFA, Biologics, and About pages. This page goes deeper: it’s the home for the detailed clinical documentation that stays within the manufacturer’s confidentiality terms — the full protocol architecture, the European study data, and the sourcing records — reserved for verified practitioners below.
Deeper clinical documentation — European study data, the full protocol architecture, and sourcing detail — is reserved for verified practitioners under the manufacturer’s confidentiality terms. Enter your access code to continue.
LIMFA’s architecture is a ladder: 29 engineered programs organize into 7 on-screen categories — Edema, Bone Restore, Neuromuscular, Muscle Relaxant, Inflammation, Analgesic, Anti-Inflammation — which in turn drive 35 condition-specific protocols. Program run time averages 60–70 minutes.
510(k) K243165, Class II (received May 2025). Cleared indications: temporary increase in local blood circulation and muscle performance. Spec: 2–80 Hz bipolar, ~100 µT.
Pain therapy, soft-tissue and bone repair, delayed bone consolidation, osteoporosis, and lesions of tendon / nerve / muscle. These are CE indications — not FDA-cleared, and they do not represent U.S.-cleared indications.
In a University of Ancona study, a +24% T-score improvement was observed over six weeks (12 treatments). This figure is Eywa/international data, scoped to the study population, and is not a representation of a U.S.-cleared outcome.
MSC exosome material is derived from Wharton’s jelly of the umbilical cord — collected at a healthy, full-term birth with maternal consent from screened donors. Material is isolated via a patented process in a cGMP-compliant facility, with third-party certificates of analysis and standard exosome surface markers (CD9 / CD63 / CD81) documented per lot. Full sourcing and sterility documentation (including Eurofins reporting) is available from your representative under NDA.
Explore the PureExos ecosystem, or talk through what fits your practice.